We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Leary investors

17 September 2020 By Rob Cox

Compass Pathways, which treats depression with a psilocybin-based compound, is raising $107 mln. It has no revenue. Its risk factors are like a bad trip. But as investors throw cash at blank-cheque firms promising visions of the future, taking a punt doesn’t seem so risky.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)